# A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

> **NCT00467649** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 112 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** pramlintide acetate (Symlin)
- **DRUG:** rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
- **DRUG:** basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])

## Key facts

- **NCT ID:** NCT00467649
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467649, "A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00467649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*